1.35
price down icon1.46%   -0.02
after-market Dopo l'orario di chiusura: 1.35
loading
Precedente Chiudi:
$1.37
Aprire:
$1.35
Volume 24 ore:
2.67M
Relative Volume:
1.62
Capitalizzazione di mercato:
$82.88M
Reddito:
$5.03M
Utile/perdita netta:
$-185.41M
Rapporto P/E:
-0.4369
EPS:
-3.09
Flusso di cassa netto:
$-139.79M
1 W Prestazione:
+4.65%
1M Prestazione:
-8.78%
6M Prestazione:
-90.22%
1 anno Prestazione:
-88.91%
Intervallo 1D:
Value
$1.31
$1.395
Intervallo di 1 settimana:
Value
$1.22
$1.4093
Portata 52W:
Value
$1.1001
$16.10

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name
Nome
Pliant Therapeutics Inc
Name
Telefono
650-481-6770
Name
Indirizzo
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
Dipendente
171
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
PLRX's Discussions on Twitter

Confronta PLRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PLRX
Pliant Therapeutics Inc
1.35 79.19M 5.03M -185.41M -139.79M -3.09
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-04 Ripresa Cantor Fitzgerald Neutral
2025-03-04 Downgrade Needham Buy → Hold
2025-03-03 Downgrade Leerink Partners Outperform → Market Perform
2025-03-03 Downgrade Stifel Buy → Hold
2025-02-10 Downgrade Canaccord Genuity Buy → Hold
2025-02-10 Downgrade Citigroup Buy → Neutral
2025-02-10 Downgrade H.C. Wainwright Buy → Neutral
2025-02-10 Downgrade JP Morgan Overweight → Neutral
2025-02-10 Downgrade Oppenheimer Outperform → Perform
2025-02-10 Downgrade RBC Capital Mkts Outperform → Sector Perform
2025-02-10 Downgrade Wells Fargo Overweight → Equal Weight
2024-09-09 Ripresa Leerink Partners Outperform
2023-12-08 Iniziato Wells Fargo Overweight
2023-05-18 Iniziato Canaccord Genuity Buy
2023-04-13 Iniziato Robert W. Baird Outperform
2022-12-14 Iniziato Stifel Buy
2022-12-07 Iniziato JP Morgan Overweight
2022-09-01 Iniziato Citigroup Buy
2022-07-20 Iniziato SVB Leerink Outperform
2022-05-25 Iniziato Cantor Fitzgerald Overweight
2021-12-10 Iniziato Oppenheimer Outperform
2021-11-24 Iniziato RBC Capital Mkts Outperform
2021-11-03 Iniziato H.C. Wainwright Buy
2021-04-20 Iniziato BTIG Research Buy
2021-04-05 Iniziato Citigroup Buy
2020-06-29 Iniziato Citigroup Buy
2020-06-29 Iniziato Cowen Outperform
2020-06-29 Iniziato Needham Buy
2020-06-29 Iniziato Piper Sandler Overweight
Mostra tutto

Pliant Therapeutics Inc Borsa (PLRX) Ultime notizie

pulisher
May 21, 2025

Pliant Therapeutics presents new fibrosis treatment data By Investing.com - Investing.com Canada

May 21, 2025
pulisher
May 21, 2025

Pliant Therapeutics Presents Clinical and Preclinical Data at th - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Pliant Therapeutics presents new fibrosis treatment data - Investing.com

May 21, 2025
pulisher
May 21, 2025

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference | PLRX Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society ... - Eagle-Tribune

May 21, 2025
pulisher
May 21, 2025

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

Breakthrough: Pliant's New Lung Disease Drug Outperforms Standard Treatment in Latest Clinical Data - Stock Titan

May 21, 2025
pulisher
May 14, 2025

How Are Things Looking For Pliant Therapeutics Inc (NASDAQ: PLRX) For The Short Term? - Stocksregister

May 14, 2025
pulisher
May 12, 2025

Cautious Hold Rating on Pliant Therapeutics Amid Clinical and Financial Uncertainties - TipRanks

May 12, 2025
pulisher
May 09, 2025

Another Bay Area biotech company announces layoffs - MSN

May 09, 2025
pulisher
May 09, 2025

Pliant Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 08, 2025

Pliant (PLRX) Prepares to Release Topline Results from BEACON-IP - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Pliant (PLRX) Prepares to Release Topline Results from BEACON-IPF Trial | PLRX Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Pliant Therapeutics reports Q1 EPS (92c), consensus (62c) - TipRanks

May 08, 2025
pulisher
May 08, 2025

Pliant Therapeutics (PLRX) Advances in Clinical Trials and Oncology Research | PLRX Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire

May 08, 2025
pulisher
May 07, 2025

Market Watch Highlights: Pliant Therapeutics Inc (PLRX) Ends on an Downturn Note at 1.43 - DWinneX

May 07, 2025
pulisher
May 05, 2025

Pliant Therapeutics Cuts Workforce by Nearly Half - Powder & Bulk Solids

May 05, 2025
pulisher
May 02, 2025

Bay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in value - MSN

May 02, 2025
pulisher
May 02, 2025

Pliant cuts workforce by 45% following lung trial termination - Clinical Trials Arena

May 02, 2025
pulisher
May 02, 2025

Pliant Therapeutics to cut 45% of workforce (PLRX:NASDAQ) - Seeking Alpha

May 02, 2025
pulisher
May 01, 2025

Pliant Therapeutics (PLRX) Restructures to Prolong Financial Res - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Pliant Therapeutics Reduces Workforce as Part of Strategic Realignment - MarketWatch

May 01, 2025
pulisher
May 01, 2025

Pliant Therapeutics (PLRX) Restructures to Prolong Financial Resources | PLRX Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Pliant Therapeutics announces workforce reduction By Investing.com - Investing.com India

May 01, 2025
pulisher
May 01, 2025

Pliant Therapeutics announces workforce reduction - Investing.com

May 01, 2025
pulisher
May 01, 2025

Pliant Therapeutics Announces Major Workforce Reduction - TipRanks

May 01, 2025
pulisher
May 01, 2025

Pliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical Trials - Nasdaq

May 01, 2025
pulisher
May 01, 2025

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations - GlobeNewswire

May 01, 2025
pulisher
May 01, 2025

Pliant Therapeutics Slashes Nearly Half its Workforce While Awaiting Crucial IPF Drug Results - Stock Titan

May 01, 2025
pulisher
May 01, 2025

You might want to take a look at Pliant Therapeutics Inc (PLRX) now - Sete News

May 01, 2025
pulisher
Apr 30, 2025

Pliant Therapeutics Inc [PLRX] stock was sold by Coulie Bernard at the price of US$0.59 million - knoxdaily.com

Apr 30, 2025
pulisher
Apr 30, 2025

Market Momentum: Pliant Therapeutics Inc (PLRX) Registers a 0.68 Increase, Closing at 1.48 - DWinneX

Apr 30, 2025
pulisher
Apr 30, 2025

Stock Performance Spotlight: Cg Oncology Inc (CGON) Ends the Day at 26.94, Down by -3.68 - DWinneX

Apr 30, 2025
pulisher
Apr 30, 2025

Pliant Therapeutics Inc (PLRX)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com

Apr 30, 2025
pulisher
Apr 29, 2025

Legal & General Group Plc Grows Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

Pliant Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - investchronicle.com

Apr 28, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 26, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc.PLRX - Louisiana First News

Apr 26, 2025
pulisher
Apr 25, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant ... - Bluefield Daily Telegraph

Apr 25, 2025
pulisher
Apr 25, 2025

Pliant Therapeutics discovers new integrin αvβ1, αvβ6 and/or αvβ8 antagonists - BioWorld MedTech

Apr 25, 2025
pulisher
Apr 25, 2025

Pliant Therapeutics Inc’s Market Journey: Closing Weak at 3.03, Down -1.62 - DWinneX

Apr 25, 2025
pulisher
Apr 24, 2025

PLRXPliant Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan

Apr 24, 2025
pulisher
Apr 24, 2025

Healthy Upside Potential: Pliant Therapeutics Inc (PLRX) - Sete News

Apr 24, 2025
pulisher
Apr 24, 2025

Market Recap Check: Pliant Therapeutics Inc (PLRX)’s Positive Finish at 1.54, Up/Down 2.67 - DWinneX

Apr 24, 2025
pulisher
Apr 23, 2025

Pliant Therapeutics Inc (PLRX)’s stock price in review: A technical analysis - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Bought by JPMorgan Chase & Co. - Defense World

Apr 23, 2025

Pliant Therapeutics Inc Azioni (PLRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):